20 articles
Neuronal signals fuel small cell lung cancer via the vagus nerve and direct neuron-to-tumor synapses, opening new therapeutic targets.
A Nature study reveals lung tumors activate vagal nerves to drive sympathetic signaling that shuts down anti-tumor immunity.
New research reveals how activating vascular STING pathways helps immune cells infiltrate and destroy aggressive lung cancer cells.
A Nature study reveals neurons physically transfer mitochondria to breast cancer cells via tunneling nanotubes, boosting metastatic potential.
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.
Engineered immune cell vesicles first induce cancer cell senescence with chemo, then eliminate them with targeted senolytic drugs.
A Phase 1/2 NCI trial tested PANVAC vaccinia and fowlpox vaccines plus immune booster sargramostim in advanced colorectal, breast, and ovarian cancers.
Antibody-drug conjugate achieved 21% response rate in heavily pretreated patients with limited options.
Phase I trial shows NT-I7 safely increases lymphocyte counts and expands cancer-fighting T cells in high-grade glioma patients.
Scientists discover IGSF11-VISTA pathway as promising target for deadly childhood brain tumors, offering hope for new treatments.
A phase 1 trial finds intraventricular nivolumab is safe for leptomeningeal metastases, with median survival of 6.6 months.
A phase 1 trial shows Temferon — a gene-engineered stem cell therapy — safely delivers interferon-α into glioblastoma tumors with no dose-limiting toxicities.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
Synthetic super-enhancers hijack glioblastoma's own regulatory circuits to trigger precise, tumor-only cell death and durable immune memory.
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
New viral therapy ASP9801 targets solid tumors directly, potentially offering hope for patients with advanced metastatic cancer.
Scientists develop safer way to deliver immune-boosting genes directly to tumors, enhancing radiation therapy effectiveness.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
First study tests whether supervised exercise training is safe and beneficial for bladder cancer patients during treatment.
